Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Short Interest Update

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) was the target of a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 406,600 shares, a decrease of 17.6% from the December 31st total of 493,500 shares. Approximately 2.7% of the company’s shares are sold short. Based on an average daily trading volume, of 66,300 shares, the short-interest ratio is currently 6.1 days.

Accelerate Diagnostics Price Performance

NASDAQ AXDX traded up $0.01 on Thursday, reaching $1.32. The company had a trading volume of 18,643 shares, compared to its average volume of 46,718. Accelerate Diagnostics has a 1 year low of $0.73 and a 1 year high of $2.09. The firm has a 50-day moving average of $1.30 and a 200-day moving average of $1.54. The firm has a market capitalization of $33.05 million, a PE ratio of -0.46 and a beta of 0.59.

Insider Transactions at Accelerate Diagnostics

In other news, Director John Patience bought 200,000 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was acquired at an average price of $1.57 per share, for a total transaction of $314,000.00. Following the acquisition, the director now owns 653,224 shares of the company’s stock, valued at $1,025,561.68. This trade represents a 44.13 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 43.60% of the company’s stock.

Institutional Investors Weigh In On Accelerate Diagnostics

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd acquired a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned about 0.08% of Accelerate Diagnostics at the end of the most recent reporting period. 17.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on AXDX. StockNews.com initiated coverage on shares of Accelerate Diagnostics in a research note on Tuesday. They set a “hold” rating for the company. BTIG Research upgraded Accelerate Diagnostics to a “strong-buy” rating in a report on Wednesday, December 11th.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.